Welcome to our dedicated page for SRX GLOBAL SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRX Global Inc. entered into a Limited Waiver and Consent Agreement with the Required Holders under its existing Securities Purchase Agreement that allows the company to return capital to common stockholders while that financing remains in place. The original agreement permits accredited investors to purchase up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million in one or more closings.
Under the Waiver, the Required Holders consent to SRX Global’s plan to declare and pay a one-time cash dividend of $0.05 per share on common stock outstanding, payable on August 3, 2026 to stockholders of record at the close of business on July 22, 2026. They also consent to a stock repurchase plan under which the company may repurchase up to the lesser of 10,000,000 shares of common stock or 50% of the issued and outstanding common stock at any given time, for an aggregate purchase price not to exceed $20,000,000, during the period ending July 7, 2027.
SRX Global Inc. has filed a prospectus supplement covering the resale by existing holders of up to 3,125,752 shares of common stock, including shares issuable from prior PIPE financings, the SRx Canada acquisition, service-based issuances and a share exchange, all adjusted for a 1‑for‑60 reverse stock split effective July 6, 2026.
The company recently closed its acquisition of EMJ Crypto Technologies and related entities, issuing 268,346,659 common shares, 117,268,196 Exchangeable Shares and Pre‑Funded Warrants for 44,368,530 shares under a previously declared‑effective Form S‑4, and changed its name from SRx Health Solutions to SRX Global while keeping the SRXH ticker.
Management reports preliminary net asset value of approximately $60 million, or $3.07 per share, with approximately $40 million in cash, more than $15 million in short‑term investments, no debt and approximately 19,517,834 common shares outstanding post‑split. The board has approved a one‑time $0.05 per‑share cash dividend (about $1 million aggregate) and authorized a share‑repurchase program of up to 10 million shares or $20 million through July 9, 2027. SRX also highlights a paper‑traded EMJX strategy that returned 24.8% from February 11 to July 10, 2026, versus a 4.2% decline in bitcoin over the same period. On July 15, 2026 NYSE American notified SRX that it had regained compliance with all continued listing standards.
SRX Global Inc. filed a prospectus supplement covering the resale, from time to time, of up to 41,781,566 shares of common stock by Keystone Capital Partners under a Common Share Purchase Agreement. The company will not receive proceeds from Keystone’s resales, though it may receive cash when it elects to sell shares to Keystone; the registered amount reflects the completed 1-for-60 reverse stock split effective July 6, 2026.
SRX Global recently closed its acquisition of EMJ Crypto Technologies and related entities, issuing an aggregate of 268,346,659 common shares, 117,268,196 exchangeable shares and 44,368,530 pre-funded warrants, and changed its name from SRx Health Solutions, Inc. to SRX Global Inc. Following the July 6 share consolidation, the company reports preliminary June 30, 2026 figures of approximately $40 million in cash, more than $15 million in short‑term investments, estimated net asset value of about $60 million or $3.07 per share, and approximately 19,517,834 shares outstanding, with no debt.
The board approved a one-time cash dividend of $0.05 per share (about $1 million in total) and authorized a share repurchase program for up to 10 million shares, or up to 50% of shares outstanding, with up to $20 million allocated. Management highlights EMJX’s AI‑driven, paper‑traded strategy, which it reports returned 24.8% from February 11 to July 10, 2026 versus Bitcoin at -4.2%, and states an intention to deploy real capital into this framework. After the reverse split, NYSE American confirmed SRX Global is back in compliance with its continued listing standards.
SRX Global Inc. reports that, on July 15, 2026, NYSE American notified the company it is back in compliance with all NYSE American LLC continued listing standards set forth in Part 10 of the NYSE American Company Guide. The company has resolved the continued listing deficiency related to Section 1003(a)(i) and (ii), which had been cited in an NYSE letter dated October 14, 2025.
According to NYSE Regulation, SRX Global’s compliance indicator “.BC” will no longer be disseminated, and the company will be removed from the NYSE American list of noncompliant issuers on the exchange’s website. SRX describes itself as an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies and strategic assets.
SRX Global Inc. outlines its newly acquired EMJX strategy, an AI-driven, multi-asset crypto treasury model that, on a paper-traded basis, generated reported returns of 26% from February 11 to July 10, 2026. A time-weighted total return of 24.8% contrasted with Bitcoin at -4.2% over the same 149-day period.
Management notes these figures come from forward-dated, documented paper trades and that live capital deployment will follow. They describe EMJX market-regime signals shifting from stress to mixed, potential licensing and ETF applications, and emphasize a strong position with $55 million in cash and short-term investments, no debt, and net asset value of $3.07 per share, alongside a million-dollar aggregate cash dividend and up to a 10-million-share buyback authorization.
SRX Global Inc. outlined a series of capital return and balance sheet updates, including a one-time cash dividend and a sizable share repurchase authorization, alongside preliminary post-acquisition metrics. The board approved a $0.05 per share special dividend, totaling approximately $1 million, payable on or about August 3, 2026 to shareholders of record on July 22, 2026, funded by profits from its SpaceX investment and related hedging strategies.
The company reported preliminary figures as of June 30, 2026 of an estimated net asset value of about $60 million, or $3.07 per share, with roughly $40 million in cash, more than $15 million in short-term investments, no debt, and approximately 19,517,834 shares outstanding after a 1-for-60 reverse split. The board also authorized a share repurchase program for up to 10 million shares, or up to 50% of shares outstanding, with $20 million allocated and potential use of Rule 10b5-1 trading plans. Management emphasized a disciplined capital allocation framework, recent EMJX acquisition, and will discuss strategy and recent developments in a virtual fireside chat on July 14, 2026.
SRx Global Inc. filed an Amendment No. 1 to its Schedule 13G/A showing that the reporting persons each report 0.0% ownership based on 21,172,106 shares of Common Stock outstanding following the closing described in the Form S-4 and a 60-for-1 reverse split effected on July 6, 2026. The Amendment supplements an Original Statement filed June 25, 2026 and reports ownership information as of the close of business on July 8, 2026.
SRX Global Inc. furnished an investor presentation under Regulation FD, dated June 26, 2026, as Exhibit 99.1 to a current report. The same materials are available on the Company’s website in the presentations section and may be used in future meetings with investors and analysts.
The Company states the information is furnished, not filed, so it is not subject to Section 18 liabilities and is not automatically incorporated into other securities filings unless specifically referenced. The report includes a standard caution that the presentation contains forward-looking statements subject to risks and uncertainties and that the Company undertakes no obligation to update them.
SRX Global Inc. (Common Stock) Schedule 13G discloses that Les Filles, LLC, Tungsten III LLC and Michael A. Parker report shared reporting status with voting and dispositive control over 78,178,797 shares each, representing 6.2% of the class. The percent is calculated using 1,270,326,395 shares outstanding following the closing of a transaction described in the issuer's Form S-4 declared effective on May 7, 2026. The filing states these ownership figures are as of the close of business on June 25, 2026 and that Mr. Parker is Manager of LF and Tungsten and may be deemed to hold voting and investment control over the shares reported.
SRX Global, Inc. received notice from NYSE American that it is not in compliance with Section 1003(f)(v) because its stock has traded at a low price for a substantial period and closed below $0.10 on June 23, 2026. Trading in the company’s common stock has been halted until a reverse split is effected.
The board and majority shareholders have authorized a 1-for-60 reverse stock split of the issued and outstanding common shares. The reverse split will be effective and shares will begin trading on a post-split basis on July 6, 2026, under the existing “SRXH” symbol with a new CUSIP.
The reverse split is intended to help the company regain compliance with NYSE American’s continued listing standards. It will apply uniformly to all shareholders, with no change to par value. Fractional positions will not be issued; instead, affected holders will receive one whole share in lieu of any fractional share.